Sharmilan Thanendrarajan
Concepts (237)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 57 | 2024 | 2929 | 4.050 |
Why?
| Hematopoietic Stem Cell Transplantation | 9 | 2024 | 565 | 1.140 |
Why?
| Leukemia, Plasma Cell | 2 | 2020 | 33 | 0.900 |
Why?
| Antibodies, Bispecific | 4 | 2024 | 60 | 0.830 |
Why?
| Immunotherapy, Adoptive | 5 | 2024 | 156 | 0.750 |
Why?
| Bone Marrow | 10 | 2022 | 362 | 0.710 |
Why?
| Neoplasms, Plasma Cell | 3 | 2024 | 37 | 0.670 |
Why?
| Plasma Cells | 6 | 2023 | 223 | 0.610 |
Why?
| Chromosome Deletion | 2 | 2023 | 140 | 0.600 |
Why?
| Transplantation, Autologous | 10 | 2024 | 466 | 0.590 |
Why?
| Humans | 66 | 2024 | 49974 | 0.590 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 2017 | 36 | 0.580 |
Why?
| Gene Expression Profiling | 10 | 2023 | 1032 | 0.560 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2017 | 202 | 0.550 |
Why?
| Clinical Trials as Topic | 4 | 2022 | 461 | 0.540 |
Why?
| Gene Expression Regulation, Neoplastic | 6 | 2021 | 828 | 0.530 |
Why?
| Neoplasm, Residual | 6 | 2022 | 165 | 0.510 |
Why?
| Proteasome Inhibitors | 1 | 2016 | 104 | 0.500 |
Why?
| Immunologic Factors | 1 | 2016 | 114 | 0.500 |
Why?
| B-Cell Maturation Antigen | 6 | 2024 | 90 | 0.490 |
Why?
| Immunotherapy | 1 | 2016 | 238 | 0.460 |
Why?
| Stem Cell Transplantation | 5 | 2024 | 181 | 0.450 |
Why?
| Translocation, Genetic | 5 | 2021 | 264 | 0.450 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 3 | 2023 | 103 | 0.440 |
Why?
| Antibodies, Monoclonal | 2 | 2022 | 459 | 0.440 |
Why?
| Mutation | 7 | 2022 | 1294 | 0.440 |
Why?
| Aged | 21 | 2024 | 9310 | 0.420 |
Why?
| Prognosis | 14 | 2024 | 1942 | 0.420 |
Why?
| Neoplasm Proteins | 4 | 2020 | 322 | 0.410 |
Why?
| Neutropenia | 2 | 2023 | 116 | 0.410 |
Why?
| Cytokine-Induced Killer Cells | 1 | 2011 | 2 | 0.390 |
Why?
| Neoplasms | 2 | 2012 | 1235 | 0.390 |
Why?
| Lymphocytes | 1 | 2012 | 152 | 0.380 |
Why?
| Cancer Vaccines | 1 | 2011 | 78 | 0.360 |
Why?
| Evolution, Molecular | 2 | 2021 | 99 | 0.360 |
Why?
| Neoplasm Recurrence, Local | 7 | 2024 | 614 | 0.360 |
Why?
| Positron-Emission Tomography | 4 | 2022 | 295 | 0.360 |
Why?
| Survival Analysis | 7 | 2021 | 653 | 0.340 |
Why?
| Diffusion Magnetic Resonance Imaging | 3 | 2019 | 123 | 0.340 |
Why?
| Cytokines | 1 | 2012 | 612 | 0.330 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 989 | 0.300 |
Why?
| Hematologic Neoplasms | 2 | 2022 | 99 | 0.300 |
Why?
| Atrial Fibrillation | 2 | 2022 | 180 | 0.280 |
Why?
| Combined Modality Therapy | 4 | 2024 | 637 | 0.280 |
Why?
| Middle Aged | 19 | 2024 | 12069 | 0.270 |
Why?
| Female | 24 | 2024 | 26472 | 0.260 |
Why?
| Fluorodeoxyglucose F18 | 4 | 2021 | 192 | 0.240 |
Why?
| Proto-Oncogene Proteins B-raf | 3 | 2020 | 79 | 0.240 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2021 | 47 | 0.240 |
Why?
| Pentaerythritol Tetranitrate | 1 | 2024 | 6 | 0.240 |
Why?
| Aged, 80 and over | 7 | 2021 | 3129 | 0.230 |
Why?
| Neoplasms, Second Primary | 1 | 2024 | 78 | 0.230 |
Why?
| Treatment Outcome | 8 | 2024 | 5141 | 0.230 |
Why?
| Male | 22 | 2024 | 25241 | 0.220 |
Why?
| Chromosomes, Human, Pair 1 | 2 | 2023 | 93 | 0.220 |
Why?
| Adult | 15 | 2024 | 13236 | 0.210 |
Why?
| Disease Progression | 6 | 2021 | 825 | 0.210 |
Why?
| Paraproteinemias | 1 | 2022 | 72 | 0.200 |
Why?
| Immunoconjugates | 1 | 2022 | 38 | 0.200 |
Why?
| Osteolysis | 1 | 2022 | 75 | 0.200 |
Why?
| Drug Approval | 1 | 2022 | 47 | 0.200 |
Why?
| Waldenstrom Macroglobulinemia | 1 | 2022 | 40 | 0.200 |
Why?
| Lymphoma, B-Cell | 1 | 2022 | 63 | 0.200 |
Why?
| Epigenomics | 1 | 2021 | 67 | 0.200 |
Why?
| Patient Participation | 1 | 2022 | 66 | 0.190 |
Why?
| T-Lymphocytes | 4 | 2024 | 338 | 0.190 |
Why?
| Genes, Tumor Suppressor | 2 | 2021 | 73 | 0.180 |
Why?
| Practice Guidelines as Topic | 1 | 2023 | 449 | 0.180 |
Why?
| Cell Cycle | 1 | 2021 | 231 | 0.180 |
Why?
| Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.180 |
Why?
| Risk Factors | 8 | 2021 | 3613 | 0.170 |
Why?
| Bone Resorption | 1 | 2022 | 304 | 0.170 |
Why?
| Bone Diseases | 1 | 2021 | 99 | 0.170 |
Why?
| Chromosomal Instability | 1 | 2019 | 16 | 0.170 |
Why?
| Gene Regulatory Networks | 1 | 2020 | 107 | 0.170 |
Why?
| Hematopoiesis, Extramedullary | 1 | 2019 | 9 | 0.170 |
Why?
| Disease-Free Survival | 5 | 2019 | 454 | 0.170 |
Why?
| Antigens, CD | 1 | 2020 | 219 | 0.170 |
Why?
| Healthcare Disparities | 1 | 2022 | 257 | 0.170 |
Why?
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 10 | 0.160 |
Why?
| Spleen | 1 | 2019 | 172 | 0.160 |
Why?
| Phosphotransferases | 1 | 2018 | 16 | 0.160 |
Why?
| Spinal Fractures | 1 | 2018 | 38 | 0.160 |
Why?
| Antineoplastic Agents | 2 | 2024 | 1171 | 0.150 |
Why?
| Brain Neoplasms | 2 | 2011 | 287 | 0.150 |
Why?
| Bacteremia | 1 | 2019 | 90 | 0.150 |
Why?
| Adipocytes | 1 | 2018 | 121 | 0.150 |
Why?
| Gene Rearrangement | 1 | 2018 | 74 | 0.150 |
Why?
| Hexokinase | 1 | 2017 | 17 | 0.150 |
Why?
| Retinoblastoma Binding Proteins | 1 | 2017 | 10 | 0.150 |
Why?
| Recurrence | 5 | 2021 | 652 | 0.140 |
Why?
| Epigenesis, Genetic | 1 | 2020 | 374 | 0.140 |
Why?
| Calcification, Physiologic | 1 | 2017 | 41 | 0.140 |
Why?
| Pelvis | 1 | 2017 | 68 | 0.140 |
Why?
| Survival Rate | 4 | 2020 | 894 | 0.140 |
Why?
| Cell Proliferation | 4 | 2023 | 1007 | 0.140 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 105 | 0.140 |
Why?
| Immunoglobulin Light Chains | 1 | 2017 | 81 | 0.140 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2017 | 92 | 0.140 |
Why?
| Clonal Evolution | 1 | 2016 | 56 | 0.130 |
Why?
| Flow Cytometry | 1 | 2018 | 476 | 0.130 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 181 | 0.130 |
Why?
| Gene Expression | 1 | 2018 | 609 | 0.130 |
Why?
| Retrospective Studies | 6 | 2024 | 6108 | 0.120 |
Why?
| Animals | 4 | 2024 | 13187 | 0.120 |
Why?
| Cystatin M | 2 | 2024 | 20 | 0.110 |
Why?
| Cross-Sectional Studies | 3 | 2023 | 1557 | 0.110 |
Why?
| Cardiovascular Diseases | 1 | 2017 | 440 | 0.100 |
Why?
| Tumor Microenvironment | 2 | 2023 | 212 | 0.100 |
Why?
| Follow-Up Studies | 3 | 2024 | 2182 | 0.100 |
Why?
| Astrocytoma | 1 | 2011 | 20 | 0.100 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2011 | 60 | 0.100 |
Why?
| Mutation Rate | 2 | 2021 | 36 | 0.090 |
Why?
| Disease Models, Animal | 1 | 2016 | 1455 | 0.090 |
Why?
| Glioma | 1 | 2011 | 79 | 0.090 |
Why?
| In Situ Hybridization, Fluorescence | 2 | 2023 | 259 | 0.090 |
Why?
| Alleles | 2 | 2021 | 250 | 0.090 |
Why?
| Genomics | 2 | 2023 | 286 | 0.090 |
Why?
| Remission Induction | 2 | 2021 | 207 | 0.090 |
Why?
| Tumor Burden | 2 | 2020 | 132 | 0.090 |
Why?
| Vaccination | 1 | 2011 | 266 | 0.080 |
Why?
| Proto-Oncogene Proteins p21(ras) | 2 | 2021 | 66 | 0.080 |
Why?
| Histones | 2 | 2021 | 312 | 0.080 |
Why?
| Transcription Factors | 2 | 2023 | 561 | 0.080 |
Why?
| DNA Copy Number Variations | 2 | 2021 | 110 | 0.080 |
Why?
| Radiopharmaceuticals | 2 | 2021 | 209 | 0.080 |
Why?
| Models, Biological | 1 | 2011 | 727 | 0.080 |
Why?
| Cell Differentiation | 2 | 2022 | 651 | 0.080 |
Why?
| Transcriptome | 2 | 2020 | 315 | 0.070 |
Why?
| Kaplan-Meier Estimate | 2 | 2019 | 466 | 0.070 |
Why?
| Imaging, Three-Dimensional | 2 | 2017 | 151 | 0.070 |
Why?
| Biopsy | 2 | 2018 | 584 | 0.060 |
Why?
| Arkansas | 2 | 2021 | 1977 | 0.060 |
Why?
| Ferritins | 1 | 2024 | 30 | 0.060 |
Why?
| Demography | 1 | 2024 | 93 | 0.060 |
Why?
| Myeloid Progenitor Cells | 1 | 2023 | 18 | 0.060 |
Why?
| X-Ray Microtomography | 1 | 2024 | 77 | 0.060 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2024 | 53 | 0.060 |
Why?
| Antibodies | 1 | 2024 | 154 | 0.060 |
Why?
| Mice | 2 | 2024 | 5739 | 0.050 |
Why?
| TNF Receptor-Associated Factor 3 | 1 | 2022 | 13 | 0.050 |
Why?
| Signal Transduction | 2 | 2021 | 1618 | 0.050 |
Why?
| Patients | 1 | 2022 | 49 | 0.050 |
Why?
| Geography | 1 | 2022 | 61 | 0.050 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2022 | 33 | 0.050 |
Why?
| Patient Selection | 1 | 2023 | 253 | 0.050 |
Why?
| United States Food and Drug Administration | 1 | 2022 | 93 | 0.050 |
Why?
| Oncogenes | 1 | 2021 | 57 | 0.050 |
Why?
| Phylogeny | 1 | 2022 | 235 | 0.050 |
Why?
| Bone Marrow Transplantation | 1 | 2022 | 116 | 0.050 |
Why?
| Dexamethasone | 1 | 2024 | 430 | 0.050 |
Why?
| Chromosome Aberrations | 1 | 2023 | 297 | 0.050 |
Why?
| Syndecan-1 | 1 | 2021 | 72 | 0.050 |
Why?
| RANK Ligand | 1 | 2022 | 179 | 0.050 |
Why?
| SOXC Transcription Factors | 1 | 2021 | 13 | 0.050 |
Why?
| Transcriptional Activation | 1 | 2021 | 121 | 0.050 |
Why?
| Clone Cells | 1 | 2021 | 74 | 0.050 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 92 | 0.050 |
Why?
| Chromatin | 1 | 2021 | 151 | 0.050 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 225 | 0.050 |
Why?
| Cyclin D2 | 1 | 2020 | 20 | 0.050 |
Why?
| Aneuploidy | 1 | 2020 | 16 | 0.050 |
Why?
| Pyrimidines | 1 | 2022 | 192 | 0.050 |
Why?
| Proto-Oncogene Proteins c-maf | 1 | 2020 | 19 | 0.050 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2020 | 31 | 0.050 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2020 | 33 | 0.050 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 2020 | 54 | 0.050 |
Why?
| Histone Code | 1 | 2020 | 32 | 0.050 |
Why?
| Cyclin D1 | 1 | 2020 | 56 | 0.050 |
Why?
| ras Proteins | 1 | 2020 | 64 | 0.050 |
Why?
| Genome, Human | 1 | 2021 | 111 | 0.050 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2020 | 75 | 0.050 |
Why?
| Protein Kinase Inhibitors | 1 | 2022 | 204 | 0.040 |
Why?
| DNA, Neoplasm | 1 | 2020 | 147 | 0.040 |
Why?
| Health Status Disparities | 1 | 2022 | 195 | 0.040 |
Why?
| DNA Mutational Analysis | 1 | 2020 | 175 | 0.040 |
Why?
| Genetic Variation | 1 | 2020 | 213 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 169 | 0.040 |
Why?
| Cell Line, Tumor | 1 | 2023 | 1403 | 0.040 |
Why?
| Osteoclasts | 1 | 2022 | 425 | 0.040 |
Why?
| Multivariate Analysis | 1 | 2021 | 577 | 0.040 |
Why?
| Gram-Positive Bacterial Infections | 1 | 2019 | 26 | 0.040 |
Why?
| Computational Biology | 1 | 2020 | 214 | 0.040 |
Why?
| Pseudomonas Infections | 1 | 2019 | 48 | 0.040 |
Why?
| Syndrome | 1 | 2019 | 237 | 0.040 |
Why?
| Fractures, Compression | 1 | 2018 | 17 | 0.040 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 427 | 0.040 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 51 | 0.040 |
Why?
| Promoter Regions, Genetic | 1 | 2020 | 475 | 0.040 |
Why?
| Oncogene Proteins, Fusion | 1 | 2018 | 58 | 0.040 |
Why?
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2017 | 8 | 0.040 |
Why?
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 27 | 0.040 |
Why?
| Protein-Tyrosine Kinases | 1 | 2018 | 95 | 0.040 |
Why?
| Kidney Function Tests | 1 | 2017 | 49 | 0.040 |
Why?
| Retinoblastoma Protein | 1 | 2017 | 19 | 0.040 |
Why?
| False Positive Reactions | 1 | 2017 | 63 | 0.040 |
Why?
| STAT3 Transcription Factor | 1 | 2017 | 81 | 0.040 |
Why?
| Fibroblast Growth Factors | 1 | 2017 | 47 | 0.040 |
Why?
| Bone and Bones | 1 | 2021 | 469 | 0.040 |
Why?
| Glomerular Filtration Rate | 1 | 2017 | 111 | 0.040 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2017 | 155 | 0.040 |
Why?
| Amino Acid Sequence | 1 | 2018 | 585 | 0.040 |
Why?
| Alkaline Phosphatase | 1 | 2017 | 94 | 0.040 |
Why?
| Sequence Analysis, DNA | 1 | 2017 | 237 | 0.030 |
Why?
| Genes, ras | 1 | 2016 | 43 | 0.030 |
Why?
| Genes, p53 | 1 | 2016 | 51 | 0.030 |
Why?
| NF-kappa B | 1 | 2018 | 314 | 0.030 |
Why?
| Glycolysis | 1 | 2016 | 70 | 0.030 |
Why?
| DNA Methylation | 1 | 2020 | 548 | 0.030 |
Why?
| Models, Genetic | 1 | 2016 | 170 | 0.030 |
Why?
| Genomic Instability | 1 | 2016 | 92 | 0.030 |
Why?
| Staphylococcal Infections | 1 | 2019 | 268 | 0.030 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2016 | 106 | 0.030 |
Why?
| Logistic Models | 1 | 2018 | 888 | 0.030 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 141 | 0.030 |
Why?
| Melphalan | 1 | 2016 | 174 | 0.030 |
Why?
| Heart | 1 | 2017 | 326 | 0.030 |
Why?
| Kidney Diseases | 1 | 2017 | 214 | 0.030 |
Why?
| Algorithms | 1 | 2018 | 615 | 0.030 |
Why?
| Echocardiography | 1 | 2017 | 378 | 0.030 |
Why?
| Time Factors | 1 | 2021 | 2903 | 0.030 |
Why?
| Myocardium | 1 | 2017 | 436 | 0.030 |
Why?
| Disease Management | 1 | 2015 | 174 | 0.030 |
Why?
| Longitudinal Studies | 1 | 2016 | 688 | 0.030 |
Why?
| Thalidomide | 1 | 2016 | 377 | 0.030 |
Why?
| Risk Assessment | 1 | 2018 | 1259 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 2016 | 1376 | 0.030 |
Why?
| Ifosfamide | 1 | 2011 | 9 | 0.020 |
Why?
| Dacarbazine | 1 | 2011 | 9 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2017 | 1159 | 0.020 |
Why?
| Carboplatin | 1 | 2011 | 53 | 0.020 |
Why?
| Etoposide | 1 | 2011 | 72 | 0.020 |
Why?
| United States | 1 | 2022 | 4860 | 0.020 |
Why?
| Treatment Failure | 1 | 2011 | 114 | 0.020 |
Why?
| Fatal Outcome | 1 | 2011 | 195 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2011 | 376 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2017 | 1537 | 0.020 |
Why?
|
|
Thanendrarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|